louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02512029: 18F-AV-1451 PET Imaging in TBI
Official title: 18F-AV-1451 PET Imaging in Subjects With Subacute Traumatic Brain Injury
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE1
Conditions: Traumatic Brain Injury
Lead sponsor: Avid Radiopharmaceuticals
Sponsor class: INDUSTRY
First posted: 2015-07-30
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: This study will evaluate imaging characteristics of 18F-AV-1451 in subjects with subacute traumatic brain injury.


Eligibility criteria: TBI Subjects

Inclusion Criteria:

TBI Subjects

* Subjects that have consented and are currently enrolled in either Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI), Evaluation, Pathogenesis, and Outcome of Subjects with or Suspected Traumatic Brain Injury Protocol Number: CNS: 10-N-N122, or Evaluation and Diagnosis of Potential Research Subjects with Traumatic Brain Injury (TBI): Protocol Number: 11-N-0084
* History of having sustained a TBI \< 6 weeks prior to enrollment
* Can tolerate PET and MRI scan procedures

Control Subjects

* MMSE ≥ 28
* No significant history of cognitive impairment
* No prior history of TBI
* Can tolerate PET and MRI scan procedures

Exclusion Criteria:

* Have behavior dysfunction that is likely to interfere with imaging
* Are claustrophobic or otherwise unable to tolerate the imaging procedure
* Have current clinically significant cardiovascular disease, or clinically significant abnormalities on screening ECG
* A history of additional risk factors for Torsades de Pointes (TdP) or are taking drugs that are known to cause QT-prolongation
* Have a current clinically significant infectious disease, endocrine or metabolic disease, pulmonary, renal or hepatic impairment, or cancer
* Are females of childbearing potential who are not surgically sterile, not refraining from sexual activity or not using reliable methods of contraception
* Have had a non-study related radiopharmaceutical imaging or treatment procedure within 7 days prior to the 18F-AV-1451 imaging session
* Have current alcohol dependence or alcohol dependence within the past 1 year
* Are currently participating in another interventional clinical trial
* Have evidence of a penetrating brain injury
* Have participated in contact sports in college or after high school age

Primary outcomes:
measure: TBI Biomarker Analysis
timeFrame: 75-105 minutes postinjection
measure: Relationship Between Clinical Presentation and Tau Deposition (MMSE)
timeFrame: 75-105 minutes postinjection
measure: Change in tau deposition over time
timeFrame: 6 months
measure: Relationship Between Clinical Presentation and Tau Deposition (BIS-11)
timeFrame: 75-105 minutes postinjection
Secondary outcomes:
Other outcomes:
Locations:
city: Bethesda
country: United States
facility: NIH Clinical Center
state: Maryland
Study officials:
affiliation: Avid Radiopharmaceuticals, Inc.
name: Chief Medical Officer
role: STUDY_CHAIR
References:
Clinical trial NCT06202729: Focus on Experienced Anxiety Related to an Emergency Department Visit
Official title: Focus on Experienced Anxiety Related to an Emergency Department Visit
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Fear
Keywords: Fear, anxiety
Lead sponsor: Frisius Medisch Centrum
Sponsor class: OTHER
First posted: 2024-01-11
Enrollment: 139
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult patients visiting the ED.

Brief summary: The aim of the present study is to determine the prevalence of anxiety in adult patients attending the ED of the Medical Centre Leeuwarden.

Detailed description: Determination of the prevalence of anxiety in adult patients attending the ED of the Medical Centre Leeuwarden. Secondarily, the common causes of anxiety and the effect of anxiety on the time of presentation to the ED and perceived pain will be investigated. In addition to gaining more insight into the relationship between the ED and anxiety, the study aims to raise awareness of anxiety among patients in the ED.

Eligibility criteria: Inclusion Criteria:

* Age 18 years and older
* Competent to decide on study participation
* Written informed consent obtained

Exclusion Criteria:

* Patients from who a Dutch questionnaire cannot be obtained (e.g. delirious, comatose, confused and non-Dutch speaking patients)
* If the reason for ED presentation is: suicide, intoxication or reporting from a sexual violence center
* Patients with an active eating disorder
* Patient already included in this study
* Objection to the use of patient data registered in the EPD

Primary outcomes:
measure: Prevalence of anxiety measured by GAD-7 and VAS-A
timeFrame: Two weeks prior to ED presentation
Secondary outcomes:
measure: Timing ER visit
timeFrame: 1 Day
measure: Start of fear (open question)
timeFrame: 1 Day
measure: Influence of pain (NRS) on fear (GAD-7)
timeFrame: 1 Day
measure: Cause of fear (open question)
timeFrame: 1 Day
Other outcomes:
Locations:
city: Leeuwarden
country: Netherlands
facility: MCLeeuwarden
state: Friesland
Study officials:
References:
Clinical trial NCT00074529: Study of MK0677 for the Treatment of Alzheimer's Disease (0677-030)(COMPLETED)
Official title: A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of MK-0677 25 mg in Slowing the Progression of Alzheimer's Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Alzheimer's Disease
Lead sponsor: Merck Sharp & Dohme LLC
Sponsor class: INDUSTRY
First posted: 2003-12-16
Enrollment: 512
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Primary purpose: TREATMENT

Brief summary: An investigational drug (MK0677) will be studied to determine whether it helps the memory and cognition of patients with Alzheimer's Disease.


Eligibility criteria: * Patients must have probable Alzheimer's disease of mild or moderate severity.
* A brain scan and laboratory results must be consistent with Alzheimer's disease.
* The patient must be otherwise medically healthy.

Primary outcomes:
measure: Cognitive function over 12 month period; safety and tolerability
timeFrame: over 12 month period
Secondary outcomes:
measure: AD symptoms over a 6 month and 12 month period measured by the CIBIC + and the ADAS-Cog.
timeFrame: over a 6 month and 12 month period
Other outcomes:
Locations:
Study officials:
affiliation: Merck Sharp & Dohme LLC
name: Medical Monitor
role: STUDY_DIRECTOR
References:
citation: Sevigny JJ, Ryan JM, van Dyck CH, Peng Y, Lines CR, Nessly ML; MK-677 Protocol 30 Study Group. Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial. Neurology. 2008 Nov 18;71(21):1702-8. doi: 10.1212/01.wnl.0000335163.88054.e7.
citation: Sevigny JJ, Peng Y, Liu L, Lines CR. Item analysis of ADAS-Cog: effect of baseline cognitive impairment in a clinical AD trial. Am J Alzheimers Dis Other Demen. 2010 Mar;25(2):119-24. doi: 10.1177/1533317509350298.
Clinical trial NCT00159029: Genetics of Alpha Thalassemia in Israeli Ethnic Groups
Official title: Haplotype Analysis of Alpha Globin Genes in Israeli Ethnic Groups
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Alpha Thalassemia
Lead sponsor: Hadassah Medical Organization
Sponsor class: OTHER
First posted: 2005-09-12
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients who come to Hadassah Hospital for anemia with microcytosis who are found to have alpha thalassemia.

Brief summary: Alpha thalassemia causes mild anemia and is found in many ethnic groups. Usually it is found in regions where malaria is endemic. We have found that alpha thalassemia is common in Ashkenazim, whose countries of origin are in temperate climates.

We are analyzing the alpha globin genes of individuals of many ethnic groups and will compare to try to define the origin of thalassemia in these individuals of European extraction.

Detailed description: Alpha thalassemia causes mild anemia and is found in many ethnic groups. Usually it is found in regions where malaria is endemic. We have found that alpha thalassemia is common in Ashkenazim, whose countries of origin are in temperate climates.

We are analyzing the alpha globin polymorphisms to determine the haplotypes of individuals of many ethnic groups and will compare to try to define the origin of thalassemia in these individuals of European extraction.

Eligibility criteria: Inclusion Criteria:

* diagnosis of deletional alpha thalassemia

Exclusion Criteria:

* under age 18

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Jerusalem
country: Israel
facility: Hadassah Medical Organization
Study officials:
affiliation: Hadassah Medical Organization
name: Deborah Rund, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Rund D, Filon D, Jackson N, Asher N, Oron-Karni V, Sacha T, Czekalska S, Oppenheim A. An unexpectedly high frequency of heterozygosity for alpha-thalassemia in Ashkenazi Jews. Blood Cells Mol Dis. 2004 Jul-Aug;33(1):1-3. doi: 10.1016/j.bcmd.2004.04.009.
Clinical trial NCT04464629: Assessing the Efficacy and Safety of DEXTENZA in Pseudo Phakic Patients Undergoing Gas Bubble Repair and Laser Following Retinal Detachment
Official title: Assessing the Efficacy and Safety of DEXTENZA, Sustained Release Dexamethasone 0.4 mg Insert, When Placed Within the Lower Eye Lid Canaliculus in Pseudo Phakic Patients Undergoing Gas Bubble Repair and Laser Following Retinal Detachment
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE4
Conditions: Retinal Detachment
Lead sponsor: Midwest Eye Institute
Sponsor class: OTHER
Collaborators: name: Ocular Therapeutix, Inc.
First posted: 2020-07-09
Enrollment: 7
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: This prospective, open-label, single-center, randomized, investigator-sponsored clinical study seeks to investigate: how will pseudophakic patients respond in terms of objective and subjective outcomes, when treated with Dextenza compared to topical prednisolone acetate following gas bubble repair and laser for RD.

Detailed description: Subjects who have given informed consent and determined to be eligible at screening will be randomized in a 1:1 ratio to DEXTENZA (placed once in the lower punctum) or the use of topical Prednisolone acetate 1% drops (four times daily). They will be observed for a period of 3-months for both pain and inflammation of the eye.

Eligibility criteria: Inclusion Criteria:

* Pseudophakic
* Retinal Detachment
* Age 18 years and older
* Scheduled for gas bubble repair and laser surgery following retinal detachment
* Willing and able to comply with clinic visits and study related procedures
* Willing and able to sign the informed consent form

Exclusion Criteria:

* Patients under the age of 18.
* Pregnancy (must be ruled out in women of child-bearing age with pregnancy test)
* Active infectious systemic disease
* Active infectious ocular or extraocular disease
* Obstructed nasolacrimal duct in the study eye(s)
* Hypersensitivity to dexamethasone
* Patients being treated with immunomodulating agents in the study eye(s)
* Patients being treated with immunosuppressants and/or oral steroids
* Patients with severe disease that warrants critical attention, deemed unsafe for the study by the investigator

Primary outcomes:
measure: Mean change in pain score
timeFrame: 30 Days
measure: Post-op pain scores
timeFrame: 30 Days
Secondary outcomes:
measure: Mean change in anterior chamber cell and flare score
timeFrame: 30 days
measure: Cystoid Macular Edema
timeFrame: 30 days
measure: Best Corrected Visual Acuity
timeFrame: 90 days
measure: Physician Ease of Dextenza insertion
timeFrame: Day 1
Other outcomes:
Locations:
city: Indianapolis
country: United States
facility: Midwest Eye Institute
state: Indiana
Study officials:
affiliation: Midwest Medical Advisors, Inc
name: Neil Finnen, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05364229: MR-guided Tumour Boost
Official title: MR-guided Tumour Boost With Stereotactic Body Radiotherapy in Prostate Cancer
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Prostate Cancer
Keywords: prostate cancer
SBRT
stereotactic body radiotherapy
tumour boost
Lead sponsor: University Health Network, Toronto
Sponsor class: OTHER
First posted: 2022-05-06
Enrollment: 40
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a single-arm feasibility study that is recruiting 40 patients with histologically-proven localized prostate cancer and MRI-defined lesion(s). Participants in this study will get MR-guided radiotherapy boost to MRI visible tumour before or after whole gland radiation. Participants will be followed-up as per standard of care schedule up to 5 years post-treatment.


Eligibility criteria: Inclusion Criteria:

* Histologically-proven localized prostate cancer.
* Low, Intermediate, and High-risk prostate cancer (ideally limited to 1 risk factor)
* Low-risk: cT1-T2a, PSA \<10, and Gleason score 6
* Intermediate-risk: cT2b-c, PSA 10-20, and/or Gleason score 7
* High-risk limited to 1 risk factor: \>T2, PSA \>20, or Gleason score \>7
* Intra-prostatic tumour(s) demonstrated on mpMRI histologically confirmed limited to =/\< 1/3 total prostate volume
* Planned for EBRT (+/- ADT)
* ECOG 0 or 1
* 18 years of age or older
* Ability to provide written informed consent to participate in the study

Exclusion Criteria:

* Prior radiotherapy to pelvis
* Radiological evidence of regional or distant metastases at the discretion of the treating physician.
* Active ulcerative colitis or Crohn's Disease, at discretion of treating physician
* Ataxia Telangectasia and SLE
* Contraindications to MRI; including patients with pacemakers/implantable cardiac defibrillator, cerebral aneurysm clips, shrapnel injury
* Severe claustrophobia

Primary outcomes:
measure: Feasibility of MR-guided Linear Acceleratorfor tumour-targeted intra-prostatic dose escalation as boost
timeFrame: Baseline
Secondary outcomes:
measure: Acute Toxicity
timeFrame: Baseline to 5-year follow-up
measure: Late Toxicity
timeFrame: Baseline to 5-year follow-up
measure: Patient-reported quality-of-life assessed by EPIC-26
timeFrame: Baseline to 5-year follow-up
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: University Health Network, Princess Margaret Hospital
state: Ontario
Study officials:
References:
Clinical trial NCT00799929: IVF Clinical Trial of Two Different Treatment Protocols.
Official title: Efficiency and Patient Satisfaction of Two Different IVF Protocols.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Infertility
Keywords: IVF Research Study
Infertility Sudy
in vitro fertilization
Mini IVF
Conventional IVF
Lead sponsor: New Hope Fertility Center
Sponsor class: OTHER
Collaborators: name: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
First posted: 2008-12-01
Enrollment: 564
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 38
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to compare two different in vitro fertilization (IVF) treatments: conventional IVF protocol and minimal stimulation IVF protocol, in terms of success rates, stress of treatment, drug-related side effects, multiple pregnancies and cost of treatment.

Detailed description: A random population of 564 sub-fertile women or couples with a female between ages of 18 and 38 years and a desire to undergo their first IVF cycle will be included in this outpatient clinical trial. The participation in this study will be approximately six months with a total of 20 to 25 visits. After successful completion of the pre-screening tests participants are randomized into one of the two arms of the study: Arm A - mini IVF protocol, and Arm B - conventional IVF protocol.

Eligibility criteria: Inclusion criteria:

* Valid indication for IVF treatment
* First IVF attempt
* Female age between 18 and 38 years
* Male partner 18 years of age or older
* Both partners STD free
* Must be able to understand that they may NOT become pregnant

Exclusion criteria:

* Not willing or able to sign the consent form
* Pre-existing medical condition preventing/interfering with IVF treatment
* Abnormal IVF screening tests, which includes Complete Blood Count, Varicella titer, Rubella titer, PAP smear, Syphilis, HIV 1\&2, Hepatitis B, Hepatitis C, Chlamydia, and Gonorrhea
* Abnormal pap smear
* Body Mass Index (BMI) falls below 18.5 or above 32.0
* Female participant with irregular menstrual cycles

Primary outcomes:
measure: Primary outcome parameter: Live birth
timeFrame: 4 Years
Secondary outcomes:
measure: Secondary outcome parameters: Biochemical pregnancy, Clinical pregnancy, Ongoing pregnancy, Multiple pregnancy rate, Miscarriage rate, Fertilization rate, Number of oocytes, Number of embryos
timeFrame: 4 Years
Other outcomes:
Locations:
city: New York
country: United States
facility: New Hope Fertility Center
state: New York
Study officials:
affiliation: New Hope Fertility Center
name: John J Zhang, MD, MSc, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Zhang JJ, Yang M, Merhi Z. Efficiency of metaphase II oocytes following minimal/mild ovarian stimulation in vitro fertilization. Fertil Res Pract. 2016 Sep 1;2:2. doi: 10.1186/s40738-016-0025-6. eCollection 2016.
Clinical trial NCT01422629: High Intensity Focused Ultrasound (HIFU) to Treat Breast Fibroadenoma
Official title: High Intensity Focused Ultrasound (HIFU) to Treat Breast Fibroadenoma: a Feasibility Study. A Multicentric, Open, Uncontrolled Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Breast Fibroadenoma
Keywords: Breast Fibroadenoma
High Intensity Focused Ultrasound
Lead sponsor: Theraclion
Sponsor class: INDUSTRY
First posted: 2011-08-24
Enrollment: 24
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: This study is a multicentre, open, uncontrolled trial for the observation of histological changes in breast fibroadenoma following high intensity focused ultrasound (HIFU).

This study will be conducted in France in 20 patients with breast fibroadenoma with indication for a surgical resection. The patient will receive an HIFU treatment and 6 months after treatment, the need of the surgery is evaluated.


Eligibility criteria: Inclusion Criteria:

* Diagnosis of breast fibroadenoma based on:Clinical examination, Ultrasound image and mammogram for women older than 35 years, and histology
* Fibroadenoma size superior at 1 cm at its largest dimension (measured by Ultrasound)

Exclusion Criteria:

* Patient pregnant or lactating
* Microcalcifications within the lesion at the mammogram.
* History of breast cancer or history of laser or radiation therapy to the target breast
* Breast implant in the target breast.
* Fibroadenoma not clearly visible on the ultrasound images (in B mode)
* Patient participating in other trials using drugs or devices

Primary outcomes:
measure: HIFU induced tissue necrosis assessed by histology of excised gland or reduction volume of fibroadenoma
timeFrame: 6 months after HIFU treatment
Secondary outcomes:
measure: Volume reduction of the fibroadenoma
timeFrame: 12 months after HIFU treatment
measure: - Pain score during the HIFU treatment evaluated by the Visual Analog Scale.
timeFrame: at treatment
measure: Percentage of patients with Adverse events
timeFrame: at 12 months follow-up
Other outcomes:
Locations:
city: Lille
country: France
facility: Hôpital Jeanne de Flandre, CHU de Lille 2 Avenue Oscar Lambret
city: Neuilly Sur Seine
country: France
facility: Hôpital Américain de Paris
Study officials:
affiliation: Hôpital Jeanne de Flandre, CHU de Lille - FRANCE
name: Loïc BOULANGER, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00207129: Effect of Capecitabine on the Pharmacokinetics of BMS-247550 and BMS-247550 on the Pharmacokinetics of Capecitabine and Its Metabolites in Patients With Advanced Malignancies
Official title: Effect of Capecitabine on the Pharmacokinetics of BMS-247550 on the Pharmacokinetics of Capecitabine and Its Metabolites in Patients With Advanced Malignancies
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Advanced Solid Tumors
Neoplasms
Lead sponsor: R-Pharm
Sponsor class: INDUSTRY
First posted: 2005-09-21
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to test how BMS-247550 (ixabepilone) affects the removal of capecitabine from the body and how capecitabine affects the removal of BMS-247550 from the body.


Eligibility criteria: Inclusion Criteria:

* Recovery from surgery or radiation therapy
* Measurable or non-measurable disease
* Available for follow-up

Exclusion Criteria:

* Neuropathy
* Uncontrolled pulmonary or cardiovascular disease
* Known history of HIV infection

Primary outcomes:
measure: Effect of capecitabine on the pharmacokinetics of BMS-247550 and to assess the effect of BMS-247550 on the pharmacokinetics of capecitabine
Secondary outcomes:
measure: Safety/Tumor response
Other outcomes:
Locations:
city: San Antonio
country: United States
facility: Local Institution
state: Texas
Study officials:
affiliation: Bristol-Myers Squibb
name: Bristol-Myers Squibb
role: STUDY_DIRECTOR
References:
Clinical trial NCT03904329: Obesity Paradox in Non Valvular Atrial Fibrillation Regarding Outcomes: Fact or Fiction
Official title: Obesity Paradox in Non Valvular Atrial Fibrillation
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Obesity Paradox
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2019-04-05
Enrollment: 1
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Obese patients with non valvular atrial fibrillation within one year from 1/6/2019 to 31/5/2020 among patients with non valvular in assuit university hospitals

Brief summary: Obesity paradox In patient with non valvular atrial fibrillation

Detailed description: Study role of obesity in outcomes of anticoagulation in patients with non valvular atrial fibrillation

Eligibility criteria: Inclusion Criteria:

* patients presented with non valvular AF
* patients on oral anticoagulant

Exclusion Criteria:

* valvular AF
* Mental illness
* History of cerebrovascular stroke
* history of bleeding tendency
* history of Chronic renal failure

Primary outcomes:
measure: Correlation between obesity and outcomes in non valvular atrial fibrillation
timeFrame: Sixth months
Secondary outcomes:
Other outcomes:
Locations:
city: Assiut
country: Egypt
facility: Kristen amir
Study officials:
References: